cagrilintide 2.5mg+semaglutide 2.5mg

This is a fixed-dose combination product being developed by Novo Nordisk. It is currently known under the code name AM833 and is part of a class of investigational therapies for weight management. It is not yet approved for use by any regulatory agency (like the FDA or EMA) and is still in clinical trials.